Judah Frommer Stock Analyst Profile - Morgan Stanley Research Coverage - Stocknear

Judah Frommer

Stock Analyst at Morgan Stanley

(5)
# 131
Out of 5,493 analysts
197
Total ratings
Success rate
Average return

44 Stocks

Name Action PT Current % Upside Ratings Updated
ABVX Abivax
Maintains: Overweight
71 101
82.84 21.92% 3 Sep 12, 2025
TRVI Trevi Therapeutics
Initiates Coverage On: Overweight
18
8.77 105.25% 1 Aug 21, 2025
APLS Apellis Pharmaceutic...
Maintains: Equal-Weight
25 26
22.37 16.23% 2 Jul 2, 2025
BPMC Blueprint Medicines
Maintains: Equal-Weight
102 129
n/a n/a 2 Jun 5, 2025
CLDX Celldex Therapeutics
Maintains: Overweight
46 43
26.14 64.5% 2 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
22 24
9.65 148.7% 2 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
31 22
33.78 -34.87% 3 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
8 6
8.39 -28.49% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
81 106
79.75 32.92% 2 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
35
11.71 198.89% 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
2.09 522.01% 1 Apr 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Equal-Weight
3
2.49 20.48% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40
2.47 1519.43% 8 Aug 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4
n/a n/a 3 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.42 815.49% 5 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
42.95 -30.15% 8 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
23
24.14 -4.72% 5 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
50
58.99 -15.24% 9 Jul 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
141
18.36 667.97% 13 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
156
n/a n/a 5 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
9
5.27 70.78% 5 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
175 138
n/a n/a 6 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 22
28.5 -22.81% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
8 7
5.54 26.35% 3 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 1
n/a n/a 4 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
11 8
8.84 -9.5% 5 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
32.68 40.76% 5 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
7 7
2.65 164.15% 6 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
51 55
54.31 1.27% 3 Feb 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
137.03 -66.43% 1 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 4
n/a n/a 1 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
14 10
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 49
104.33 -53.03% 4 Nov 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
328 370
915.95 -59.6% 2 Oct 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 31
76.59 -59.52% 6 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 76
81.96 -7.27% 8 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
182
102.08 78.29% 6 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
107
95.06 12.56% 13 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
90 95
132.4 -28.25% 10 Jul 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
18
17.55 2.56% 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
93 116
154.76 -25.05% 12 Jun 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 38
93.1 -59.18% 4 May 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 22
109.88 -79.98% 1 May 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
33 35
65.46 -46.53% 9 Apr 29, 2020